New and emerging LDL-C lowering agents, including inhibitors of ATP-citrate lyase, PCSK9, ANGPTL3, and CETP, offer strategies to address residual ASCVD risk in patients not reaching targets on statins.
This review discusses emerging LDL-C lowering therapies, including inhibitors of ATP-citrate lyase, PCSK9, ANGPTL3, and CETP, to address residual ASCVD risk in patients not reaching targets with statins.
Multiple lines of evidence demonstrate that low-density lipoprotein-cholesterol causes atherosclerotic cardiovascular disease. Thus, targeting and lowering low-density lipoprotein-cholesterol is the principal strategy to reduce cardiovascular disease risk in primary and secondary prevention. Statin therapy is the foundation of lipid-lowering treatment, but adherence rates are low, and many individuals do not attain target low-density lipoprotein-cholesterol values. Additionally, most statin-treated patients are still at considerable atherosclerotic cardiovascular disease risk, emphasizing the need for more aggressive low-density lipoprotein-cholesterol-lowering therapies. The purpose of this review is to discuss new and emerging approaches to further lower low-density lipoprotein-cholesterol, including inhibition of ATP-citrate lyase, proprotein convertase subtilisin-kexin type 9, angiopoietin-related protein 3, and cholesteryl ester transfer protein.
Rikhi et al. (Mon,) conducted a review in Atherosclerotic cardiovascular disease. New and emerging LDL-C lowering agents (ATP-citrate lyase, PCSK9, ANGPTL3, and CETP inhibitors) was evaluated. New and emerging LDL-C lowering agents, including inhibitors of ATP-citrate lyase, PCSK9, ANGPTL3, and CETP, offer strategies to address residual ASCVD risk in patients not reaching targets on statins.